A. Fleury

Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis

U. Schmid, M. Freiwald, Karl-Heinz Liesenfeld, 2017, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine

I. Trocóniz, H. Fritsch, M. Freiwald, 2018, Clinical Pharmacokinetics.

A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551.

T. Lavé, F. Jonsson, L. Polonchuk, 2011, Journal of pharmacological and toxicological methods.

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

A. Staab, U. Schmid, M. Freiwald, 2014, Cancer Chemotherapy and Pharmacology.

Challenges and opportunities with modelling and simulation in drug discovery and drug development

T Lavé, N Parrott, H P Grimm, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

I. Michon, Tobias Kanacher, V. Nock, 2020, Pharmaceutics.